natgillin/translations-raw huggingface dataset:
Arixtra 5 mg/0.4 ml solution for injection, pre-filled syringe. 
Arixtra 5 mg/0,4 ml raztopina za injiciranje, napolnjena injekcijska brizga
• syringe with a magenta plunger and an automatic safety system 
• injekcijska brizga z vijoličastim batom in samodejnim varnostnim sistemom.
NAME OF THE MEDICINAL PRODUCT Arixtra 7.5 mg/0.6 ml solution for injection fondaparinux sodium 
Arixtra 7,5 mg/0,6 ml raztopina za injiciranje natrijev fondaparinuksat
The syringe needle shield contains latex that has the potential to cause allergic reactions in latex sensitive individuals. 
Ščitnik igle na injekcijski brizgi vsebuje lateks, ki lahko osebam, občutljivim na lateks, povzroči resno alergijsko reakcijo.
Package leaflet: Information for the user Arixtra 2.5 mg/0.5 ml solution for injection fondaparinux sodium 
Navodilo za uporabo Arixtra 2,5 mg/0,5 ml raztopina za injiciranje natrijev fondaparinuksat
B. 
② Bat
NAME OF THE MEDICINAL PRODUCT Arixtra 2.5 mg/0.5 ml solution for injection fondaparinux sodium 
Arixtra 2,5 mg/0,5 ml raztopina za injiciranje natrijev fondaparinuksat
• syringe with yellow plunger and a manual safety system. 
• injekcijska brizga z rumenim batom in ročnim varnostnim sistemom.
→ Tell your doctor if any of these applies to you. 
→ Če se karkoli od navedenega nanaša na vas, o tem obvestite svojega zdravnika.
• syringe with blue plunger and a manual safety system. 
• injekcijska brizga z modrim batom in ročnim varnostnim sistemom.
• increase in some chemical (enzymes) produced by the liver 
• povečane vrednosti bilirubina (snovi, ki nastaja v jetrih) v krvi;
EU/1/02/206/031 - 2 pre-filled syringes with a manual safety system EU/1/02/206/032 - 10 pre-filled syringes with a manual safety system EU/1/02/206/035 - 20 pre-filled syringes with a manual safety system 
EU/1/02/206/031 - 2 napolnjeni injekcijski brizgi z ročnim varnostnim sistemom EU/1/02/206/032 - 10 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom EU/1/02/206/035 - 20 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom
Clinical experience is limited in patients with body weight <50 kg. Fondaparinux should be used with caution at a daily dose of 5 mg in this population (see sections 4.2 and 5.2). 
V tej skupini je treba fondaparinuks previdno uporabljati v dnevnem odmerku 5 mg (glejte poglavji 4.2 in 5.2).
EU/1/02/206/005- 2 pre-filled syringes with an automatic safety system EU/1/02/206/006 - 7 pre-filled syringes with an automatic safety system EU/1/02/206/007 - 10 pre-filled syringes with an automatic safety system EU/1/02/206/008 - 20 pre-filled syringes with an automatic safety system 
EU/1/02/206/005 - 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom EU/1/02/206/006 - 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/007 - 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/008 - 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
STATEMENT OF ACTIVE SUBSTANCE(S) One pre-filled syringe (0.4 ml) contains 5 mg fondaparinux sodium. 
Ena napolnjena injekcijska brizga (0,4 ml) vsebuje 5 mg natrijevega fondaparinuksata.
EU/1/02/206/015 - 2 pre-filled syringes with an automatic safety system EU/1/02/206/016 - 7 pre-filled syringes with an automatic safety system EU/1/02/206/017 - 10 pre-filled syringes with an automatic safety system EU/1/02/206/020 - 20 pre-filled syringe with an automatic safety system 
EU/1/02/206/015 - 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom EU/1/02/206/016 - 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/017 - 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/020 - 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
This dose may be reduced to 7.5 mg once a day if you have moderate kidney disease. 
Če imate zmerno okvaro ledvic, se lahko ta odmerek zmanjša na 7,5 mg enkrat na dan.
NAME OF THE MEDICINAL PRODUCT Arixtra 5 mg/0.4 ml solution for injection fondaparinux sodium 
Arixtra 5 mg/0,4 ml raztopina za injiciranje natrijev fondaparinuksat
EU/1/02/206/027 - 2 pre-filled syringes with a manual safety system EU/1/02/206/028 - 10 pre-filled syringes with a manual safety system EU/1/02/206/033 - 20 pre-filled syringes with a manual safety system 
EU/1/02/206/027- 2 napolnjeni injekcijski brizgi z ročnim varnostnim sistemom EU/1/02/206/028- 10 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom EU/1/02/206/033- 20 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom
MI or TVR at Day 30 
30. dan
EU/1/02/206/012- 2 pre-filled syringes with an automatic safety system EU/1/02/206/013 - 7 pre-filled syringes with an automatic safety system EU/1/02/206/014 - 10 pre-filled syringes with an automatic safety system EU/1/02/206/019 - 20 pre-filled syringe with an automatic safety system 
EU/1/02/206/012 - 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom EU/1/02/206/013 - 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/014 - 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/019 - 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
EU/1/02/206/001 - 2 pre-filled syringes with an automatic safety system EU/1/02/206/002 - 7 pre-filled syringes with an automatic safety system EU/1/02/206/003 - 10 pre-filled syringes with an automatic safety system EU/1/02/206/004 - 20 pre-filled syringes with an automatic safety system 
EU/1/02/206/001 - 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom EU/1/02/206/002 - 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/003 - 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/004 - 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
The needle protection system of the Arixtra pre-filled syringes have been designed with a safety system to protect from needle stick injuries following injection. 
Arixtra napolnjene injekcijske brizge so opremljene s sistemom za zaščito igle.
EU/1/02/206/009- 2 pre-filled syringes with an automatic safety system EU/1/02/206//010 - 7 pre-filled syringes with an automatic safety system EU/1/02/206/011 - 10 pre-filled syringes with an automatic safety system EU/1/02/206/018 - 20 pre-filled syringe with an automatic safety system 
EU/1/02/206/009 - 2 napolnjeni injekcijski brizgi s samodejnim varnostnim sistemom EU/1/02/206/010 - 7 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/011 - 10 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom EU/1/02/206/018 - 20 napolnjenih injekcijskih brizg s samodejnim varnostnim sistemom
Parts of the syringes: 1 Needle shield 2 Plunger 3 Finger-grip 4 Security sleeve 
② Bat ③ Držalo za prste ④ Varnostni tulec
Hepatobiliary disorders Uncommon: hepatic enzymes increased, hepatic function abnormal 
Občasni: povečana aktivnost jetrnih encimov, motnje v delovanju jeter Redki: bilirubinemija
Haemorrhage 
Žilne bolezni
Common: bleeding (haematoma, haematuria, haemoptysis, gingival bleeding) Uncommon: anaemia 
Pogosti: krvavitve (hematom, hematurija, hemoptiza, krvavitve dlesni)
EU/1/02/206/029 - 2 pre-filled syringes with a manual safety system EU/1/02/206/030 - 10 pre-filled syringes with a manual safety system EU/1/02/206/034 - 20 pre-filled syringes with a manual safety system 
EU/1/02/206/029- 2 napolnjeni injekcijski brizgi z ročnim varnostnim sistemom EU/1/02/206/030- 10 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom EU/1/02/206/034- 20 napolnjenih injekcijskih brizg z ročnim varnostnim sistemom
• indigestion 
• kašljanje;
Skin and subcutaneous tissue disorders 
Bolezni jeter, žolčnika in žolčevodov
Contents of the pack and other information 
5 Shranjevanje zdravila Arixtra Vsebina pakiranja in dodatne informacije
• drowsiness or tiredness 
• kožni izpuščaj ali srbenje;
Fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight ≥ 50kg, ≤ 100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5-2.5 times aPTT control value. 
(telesna masa < 50 kg), 7,5 mg (telesna masa > 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan z i.v.
Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) OASIS 5 was a double-blind, randomised, non-inferiority study with fondaparinux 2.5 mg subcutaneously once daily versus enoxaparin 1 mg/kg subcutaneously twice daily in approximately 20,000 patients with UA/NSTEMI. 
Pri približno 20.000 bolnikih z UA/NSTEMI je primerjala uporabo fondaparinuksa v odmerku 2,5 mg subkutano enkrat na dan in enoksaparina v odmerku 1 mg/kg subkutano dvakrat na dan.
For prevention of VTE- Agents that may enhance the risk of haemorrhage should not be administered concomitantly with fondaparinux. 
Pri preprečevanju VTE - Sočasno s fondaparinuksom se ne sme uporabljati učinkovin, ki lahko povečajo tveganje za krvavitev.
Peri-PCI major bleeding or death, 
Večja krvavitev ali smrt v času okrog PCI, MI ali TVR
B. PACKAGE LEAFLET 
vredn ost p
• chest pain 
• bolečine v prsih;
Outcome of re-examination 
Izid ponovne presoje
The additional measures proposed by the company were still considered insufficient. 
Dodatni ukrepi, ki jih je predlagala družba, so se še vedno šteli kot nezadostni.
The applicant requested a re-examination of the negative opinion. 
Predlagatelj je zahteval ponovno presojo negativnega mnenja.
What did the company present to support its application? 
Kaj je družba predložila v podporo svoji vlogi?
It was to be available as 50 mg tablets. 
Na voljo naj bi bilo v obliki 50 mg tablet.
This will stop the symptoms of migraine: headache, sickness and sensitivity to light. 
To ustavi simptome migrene: glavobol, slabost in občutljivost za svetlobo.
What were the CHMP's main concerns that led to the refusal? 
Kateri so bili glavni zadržki odbora CHMP za zavrnitev?
During the re-examination in November 2011, the CHMP's main concerns were not resolved. 
Med ponovno presojo novembra 2011 glavni zadržki odbora CHMP niso bili odpravljeni.
The CHMP therefore confirmed its initial negative opinion. 
Zato je Odbor potrdil svoje prvotno negativno mnenje.
This leads to a widening of blood vessels in the brain which can lead to a migraine attack. 
Posledično se razširijo krvne žile v možganih, kar lahko privede do migrenskega napada.
Sumatriptan will help blood vessels to return to their normal size. 
Sumatriptan pomaga, da se krvne žile vrnejo v normalno velikost.
After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 17 November 2011. 
Po proučitvi podlage za to zahtevo je odbor CHMP ponovno pregledal prvotno mnenje in 17. novembra 2011 potrdil zavrnitev vloge za dovoljenje za promet z zdravilom.
The company presented the results of a study carried out to investigate whether it is ‘bioequivalent' to the reference medicine and data in support of its use in the non-prescription setting. 
Družba je predložila rezultate študije, ki je bila izvedena, da bi raziskali, ali je zdravilo „biološko enakovredno“ referenčnemu zdravilu, in podatke v podporo uporabi brez recepta.
The CHMP felt that the measures proposed by the company to reduce these risks were insufficient. 
Odbor je menil, da so bili ukrepi za zmanjšanje teh tveganj, ki jih je predlagala družba, nezadostni.
Migraine attacks occur when the level of 5hydroxytryptamine in the brain becomes low. 
Migrenski napadi se pojavijo, ko se zniža raven 5-hidroksitriptamina v možganih.
This was because a lack of medical supervision and monitoring of the patient would increase the risk for cerebrovascular (brain) and cardiovascular (heart) side effects and potential misuse and overuse. 
Pomanjkanje zdravniškega nadzora in spremljanja bolnika bi namreč povečalo tveganje za cerebrovaskularne (možganske) in kardiovaskularne (srčne) neželene učinke ter za morebitno zlorabo in čezmerno uporabo zdravila.
Refusal of the marketing authorisation for Sumatriptan Galpharm 50 mg tablets 
Zavrnitev dovoljenja za promet z zdravilom Sumatriptan Galpharm 50 mg tablete
that allow nerve cells to communicate with one another. 
kemične snovi, ki omogočajo medsebojno sporazumevanje živčnih celic.
On 21 July 2011, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Sumatriptan Galpharm, intended for the relief of migraine attacks in people who have been diagnosed with migraine. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je 21. julija 2011 sprejel negativno mnenje, v katerem je priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Sumatriptan Galpharm, namenjenim lajšanju migrenskih napadov pri ljudeh z diagnozo migrene.
Neurotransmitters are chemicals 
Živčni prenašalci so
The active substance in Sumatriptan Galpharm and Imigran, sumatriptan, works by mimicking the action of the neurotransmitter 5-hydroxytryptamine (serotonin) in the brain. 
Zdravilna učinkovina v zdravilih Sumatriptan Galpharm in Imigran, sumatriptan, deluje tako, da posnema delovanje živčnega prenašalca 5-hidroksitriptamina (serotonina) v možganih.
The CHMP also remained concerned about the safety of Sumatriptan Galpharm, in particular the potential for misuse and overuse as well as the risk of misdiagnosis of migraine and lack of medical follow-up when used in the non-prescription setting. 
Odbor je prav tako obdržal zadržke glede varnosti zdravila Sumatriptan Galpharm, še zlasti glede morebitne zlorabe in čezmerne uporabe ter tveganja za napačno diagnozo migrene in pomanjkanje zdravniškega nadzora, kadar se zdravilo izdaja brez recepta.
Sumatriptan Galpharm was intended to be similar to a ‘reference medicine' already authorised in the European Union called Imigran. 
Zdravilo Sumatriptan Galpharm naj bi bilo podobno „referenčnemu zdravilu“ Imigran, ki je že odobreno v Evropski uniji.
Refusal of the marketing authorisation for Sumatriptan Galpharm 50 mg tablets EMA/CHMP/896315/2011 
Zavrnitev dovoljenja za promet z zdravilom Sumatriptan Galpharm 50 mg tablete EMA/159017/2012
The company that applied for authorisation is Galpharm Healthcare Ltd. 
Vlogo za dovoljenje je predložila družba Galpharm Healthcare Ltd.
Sumatriptan Galpharm is a medicine that contains the active substance sumatriptan. 
Sumatriptan Galpharm je zdravilo, ki vsebuje zdravilno učinkovino sumatriptan.
Therefore, at that point in time, the CHMP was of the opinion that the benefits of Sumatriptan Galpharm did not outweigh its risks and recommended that it be refused marketing authorisation. 
Posledično je tedaj menil, da koristi zdravila Sumatriptan Galpharm ne odtehtajo z njim povezanih tveganj, in priporočil zavrnitev dovoljenja za promet s tem zdravilom.
What is Sumatriptan Galpharm? 
Kaj je zdravilo Sumatriptan Galpharm?
In addition the CHMP felt that Sumatriptan Galpharm in the non-prescription setting is not appropriate because migraine as a condition changes over time as well as the patient's cardiovascular and cerebrovascular status, and monitoring is therefore essential. 
Odbor je menil, da izdajanje zdravila Sumatriptan Galpharm brez recepta ni primerno tudi zato, ker se migrensko obolenje sčasoma spreminja, tako kot tudi kardio- in cerebrovaskularni status bolnika.
Sumatriptan Galpharm was expected to be used to relieve migraine attacks in people who had been diagnosed with migraine. 
Zdravilo Sumatriptan Galpharm naj bi se uporabljalo za lajšanje migrenskih napadov pri ljudeh z diagnozo migrene.
In July 2011, the CHMP was concerned that Sumatriptan Galpharm in the non-prescription setting was not approvable. 
Julija 2011 je imel odbor CHMP zadržke, da ne more podpreti izdajanja zdravila Sumatriptan Galpharm brez recepta.
Sumatriptan Galpharm was expected to work in the same way as the reference medicine, Imigran. 
Zdravilo Sumatriptan Galpharm naj bi delovalo enako kot referenčno zdravilo Imigran.
Sumatriptan Galpharm was to be made available without prescription. 
Izdaja zdravilo Sumatriptan Galpharm naj bi bila brez recepta.
How is Sumatriptan Galpharm expected to work? 
Kako naj bi zdravilo Sumatriptan Galpharm delovalo?
What was Sumatriptan Galpharm expected to be used for? 
Za kaj naj bi se zdravilo Sumatriptan Galpharm uporabljalo?
This summary was last updated in 03-2015. 
Povzetek je bil nazadnje posodobljen 03-2015.
The company is also carrying out an observational study on the long-term safety of the medicine. 
Družba trenutno izvaja tudi opazovalno študijo o dolgotrajni varnosti zdravila.
It is available as tablets (500 micrograms). 
Na voljo je v obliki tablet (500 mikrogramov).
FEV1 is the most air a person can breathe out in one second. 
FEV1 je največja količina zraka, ki jo oseba lahko izdihne v eni sekundi.
What measures are being taken to ensure the safe and effective use of Daliresp? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Daliresp?
The European Commission granted a marketing authorisation valid throughout the European Union for Daliresp on 28 February 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Daliresp, veljavno po vsej Evropski uniji, izdala 28. februarja 2011.
At the beginning of the study, both groups of patients had an FEV1 of around 1 litre (1,000 ml). 
Na začetku študije sta imeli obe skupini bolnikov vrednost FEV1 okoli 1 litra (1 000 ml).
This benefit was seen on top of the effects of the treatments that the patients were already receiving. 
Korist je bila vidna kot dodatek učinkom zdravljenj, ki so jih bolniki že prejemali.
The full EPAR for Daliresp can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Daliresp je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The patients could continue to receive treatment with a bronchodilator during the study. 
Bolniki so med študijo lahko nadaljevali zdravljenje z bronhodilatorjem.
This is a summary of the European public assessment report (EPAR) for Daliresp. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Daliresp.
Patients may need to take Daliresp for several weeks before it starts to have an effect. 
Bolniki morajo jemati zdravilo Daliresp več tednov, preden se pokaže njegov učinek.
This authorisation was based on the authorisation granted to Daxas in 2010 (‘informed consent'). 
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Daxas, ki je bilo izdano leta 2010 (uporaba dokumentacije s soglasjem).
Daliresp must not be used in patients who have moderate or severe problems with their liver. 
Zdravila Daliresp ne smejo uporabljati bolniki z zmernimi ali hudimi težavami z jetri.
In addition, the company that makes Daliresp will ensure that healthcare professionals who will prescribe the medicine in all Member States of the European Union (EU) are provided with educational materials containing information on the medicine's side effects and how it should be used. 
Poleg tega bo družba, ki izdeluje zdravilo Daliresp, zagotovila, da bodo v vseh državah članicah Evropske unije (EU) zdravstveni delavci, ki bodo predpisovali zdravilo, prejeli izobraževalno gradivo o neželenih učinkih zdravila in njegovi uporabi.
For more information about treatment with Daliresp, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Daliresp preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Daliresp 
Druge informacije o zdravilu Daliresp
In addition, the patients who took Daliresp had an average of 1.1 moderate or severe flare-ups of their disease, compared with 1.4 flare-ups in the patients who took placebo. 
Poleg tega so imeli bolniki, ki so jemali zdravilo Daliresp, v povprečju 1,1 zmernega ali hudega izbruha bolezni v primerjavi z 1,4 izbruha pri bolnikih, ki so jemali placebo.
The company will also provide cards for patients, telling them what information that they need to give their doctor about their symptoms and past illnesses to help the doctor know whether Daliresp is appropriate for them. 
Zagotovila bo tudi kartice za bolnike z informacijami, ki jih morajo sporočiti zdravniku o simptomih in preteklih boleznih, da bo ta lahko presodil, ali je zdravilo Daliresp zanje primerno.
After considering all of the available data on the effects of the medicine, the Committee decided that Daliresp's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je ob upoštevanju vseh razpoložljivih podatkov o učinkih zdravila zaključil, da so koristi zdravila Daliresp večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Daliresp is not used on its own but as an ‘add-on' to treatment with bronchodilators (medicines that widen the airways in the lungs). 
Zdravilo Daliresp se ne uporablja samostojno, ampak kot „dodatek“ k zdravljenju z bronhodilatorji (zdravili, ki širijo dihalne poti v pljučih).
Daliresp is a medicine that contains the active substance roflumilast. 
Daliresp je zdravilo, ki vsebuje zdravilno učinkovino roflumilast.
The card will include an area where patients can record their weight. 
Na kartici bo tudi prostor, kjer bodo bolniki lahko beležili svojo telesno maso.
A risk management plan has been developed to ensure that Daliresp is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Daliresp je bil pripravljen načrt obvladovanja tveganj.
The active substance in Daliresp, roflumilast, belongs to a group of medicines called ‘phosphodiesterase type 4 (PDE4) inhibitors'. 
Zdravilna učinkovina v zdravilu Daliresp, roflumilast, spada v skupino zdravil, ki jih imenujemo „zaviralci fosfodiesteraze tipa 4 (PDE4)“.
What benefit has Daliresp shown during the studies? 
Kakšne koristi je zdravilo Daliresp izkazalo med študijami?
By blocking the action of PDE4, roflumilast reduces the inflammation in the lungs, helping to reduce the patient's symptoms or to prevent them from getting worse. 
Ker roflumilast zavira delovanje PDE4, zmanjša vnetje pljuč, kar pripomore k zmanjšanju bolnikovih simptomov ali prepreči njihovo poslabšanje.
Because patients taking Daliresp may lose weight, they are advised to weigh themselves on a regular basis. 
Ker lahko bolniki, ki jemljejo zdravilo Daliresp, shujšajo, jim je treba svetovati redno tehtanje.
The most common side effects with Daliresp (seen in between 1 and 10 patients in 100) are decreased weight, decreased appetite, insomnia (difficulty sleeping), headache, diarrhoea, nausea (feeling sick) and abdominal pain (stomach ache). 
Najpogostejši neželeni učinki zdravila Daliresp (opaženi pri 1 do 10 bolnikih od 100) so zmanjšana telesna masa, zmanjšan tek, nespečnost (motnje spanca), glavobol, driska, navzeja (slabost) in bolečine v trebuhu.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Daliresp. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The main measure of effectiveness was the improvement in forced expiratory volumes (FEV1) and the reduction in the number of moderate or severe flare-ups of their COPD over a year of treatment. 
Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna (FEV1) in zmanjšanje števila zmernih ali hudih izbruhov kronične obstruktivne pljučne bolezni v enem letu zdravljenja.
After a year, the patients who took Daliresp had an average increase of 40 ml while those given placebo had an average decrease of 9 ml. 
Po enem letu so imeli bolniki, ki so jemali zdravilo Daliresp, v povprečju 40 ml večjo vrednost FEV1, medtem ko se je pri tistih, ki so prejemali placebo, ta vrednost zmanjšala za 9 ml.